Hyperbaric Oxygen for COVID-19 Patients
Clara Health

Hyperbaric Oxygen for COVID-19 Patients

Sponsored by NYU Langone Health


Hyperbaric oxygen therapy (HBOT) treatment will be provided to patients as an adjunct to standard therapy for a cohort of 40 COVID19-positive patients with respiratory distress at NYU Winthrop Hospital. All patients prior to the clinical application of HBOT will be evaluated by the primary care team and hyperbaric physician.

About 
COVID-19

Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a novel coronavirus that was first identified during an investigation into an outbreak in Wuhan, China.

How is this study designed?

Study Type: Interventional (Clinical Trial) Estimated Enrollment: 40 participants Primary Purpose: Treatment Actual Study Start Date: April 6, 2020 Estimated Study Completion Date: July 2020

Who is this study for?

Inclusion Criteria: In order to be eligible to participate in this study, an individual must meet all of the following criteria: - Male or female, age > 18 years - Positive COVID 19 test - Respiratory compromise defined by SpO2 <93% - Ability to sign informed consent

Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this study: - Pregnancy - Untreated Pneumothorax

What should I expect?

  • Patients that meet inclusion criteria will be consented by the hyperbaric physician.
  • They will then be transported from the ED or other unit to the hyperbaric unit maintaining airborne precautions based on the most current hospital protocol. All study personnel will have proper PPE at all times.
  • The patient will then be placed into the monoplace chamber and when the chamber door is closed the patient will remove any respiratory filter/mask that was placed.
  • The patient will receive 90 minutes of hyperbaric oxygen at 2.0 ATA with or without airbreaks per the hyperbaric physician.
  • Upon completion of the treatment the patient will then return to the medical unit and continue all standard of care. Additional treatments (up to 5) can be given if warranted and agreed upon by the patient and all members of the team caring for the patient.
  • After the intervention portion of this study, a chart review will be performed to compare the outcomes of intervention patients versus patients who received standard of care.
Inpatient trial

Have questions or need help?

For general questions about COVID-19 clinical trials, please email [email protected] For study specific inquiries, submit the interest form and you'll be connected to the team.